Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.
Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.
复制标题
急性髓系白血病诱导化疗后的克隆造血。
DOI：
10.1056/nejme1802610
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Ebert,BenjaminL
中科院分区：
文献类型：
--
作者：
Steensma,DavidP;Ebert,BenjaminL
急性髓性白血病（AML）的成功强化诱导化疗可使诊断时存在的1万亿个恶性细胞减少至少2至4 log 10，通常在治疗开始后一个月内恢复正常的血小板和中性粒细胞水平-这是一个短期治疗的令人印象深刻的结果。超过一半的AML患者在蒽环类药物和阿糖胞苷强化诱导治疗后达到缓解，但复发很常见。预测个体患者复发的可能性有助于调整缓解后治疗的强度。. .
Successful intensive induction chemotherapy for acute myeloid leukemia (AML) results in at least a 2 to 4 log10reduction in the 1 trillion malignant cells that are present at diagnosis, often with recovery of normal platelet and neutrophil levels within a month after treatment initiation — an impressive result for a short course of treatment. More than half of patients with AML achieve remission after intensive induction therapy with an anthracycline and cytarabine, but relapse is common. Predicting the likelihood of relapse for an individual patient can be helpful in tailoring the intensity of postremission treatment.1Even when a patient . . .